Related Experiment Videos
Adverse pregnancy outcome in the antiphospholipid syndrome: focus for future research
1Department of Obstetrics and Gynaecology, St Thomas Hospital, London, UK.
Insights
Antiphospholipid syndrome (APS) in pregnancy causes severe complications like pre-eclampsia and fetal growth restriction, leading to preterm birth. Understanding APS
Area of Science:
- Obstetrics and Gynecology
- Immunology
- Maternal-Fetal Medicine
Background:
- Antiphospholipid syndrome (APS) is associated with adverse pregnancy outcomes, including recurrent pregnancy loss, pre-eclampsia, intrauterine growth restriction, and placental abruption.
- These complications frequently lead to premature delivery and subsequent neonatal issues.
- The precise mechanisms driving these poor pregnancy outcomes in APS remain unclear.
Purpose of the Study:
- To elucidate the underlying mechanisms of adverse pregnancy outcomes in pregnant patients with APS.
- To identify key research areas for enhancing the understanding of APS pathogenesis in pregnancy.
- To inform strategies for the safe and successful management of APS during pregnancy.
Main Methods:
- This article reviews current understanding and highlights areas for future research.
- It explores potential etiological pathways, distinguishing between maternal disease and primary placental involvement.
- Focus is placed on the role of antiphospholipid antibodies in placental pathology.
Main Results:
- The pathogenesis of APS-related pregnancy complications is not fully established.
- Two primary hypotheses exist: maternal disease with secondary placental issues, or direct placental damage by antiphospholipid antibodies.
- Further research is needed to differentiate these mechanisms.
Conclusions:
- Understanding the etiology and pathogenic mechanisms of APS in pregnancy is crucial for effective treatment.
- Targeted research is essential to improve outcomes for pregnant patients with APS.
- Clarifying the role of antiphospholipid antibodies in placental dysfunction is a key research priority.
Abstract:
Pregnant patients with antiphospholipid syndrome (APS) may suffer from recurrent pregnancy loss, pre-eclampsia, intrauterine growth restriction and placental abruption. These conditions inevitably result in a high incidence of premature delivery with all the neonatal complications that follow. The mechanism underlying these adverse pregnancy outcomes has not yet been established. This may be primarily a maternal disease process with secondary placental maldevelopment and/or malfunction. Alternatively, there may be primary placental damage mediated directly or indirectly by antiphospholipid antibodies. The safe and successful treatment of pregnant women with APS lies in the understanding of the aetiology of this condition and the mechanism by which complications in pregnancy may arise. In this article we highlight areas in which research may be targeted such that our understanding of the pathogenesis of adverse pregnancy outcome may be enhanced.